Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.79 |
| ▸ | CCR2 | P41597 | 2/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171659 | 1.00 | ROCK2 (0.79) | ROCK2CCR2ROCK1 | |
| SCHEMBL10139589 | 1.00 | ROCK2 (0.79) | ROCK2CCR2ROCK1 | |
| SCHEMBL10171394 | 0.93 | ROCK2 (0.80) | ROCK2CCR2ROCK1 | |
| SCHEMBL10139499 | 0.93 | ROCK2 (0.80) | ROCK2CCR2ROCK1 | |
| SCHEMBL434205 | 0.88 | ROCK2 (1.00) | ROCK2CCR2ROCK1 | |
| SCHEMBL2802556 | 0.88 | ROCK2 (1.00) | ROCK2CCR2ROCK1 | |
| SCHEMBL2801099 | 0.88 | ROCK2 (1.00) | ROCK2CCR2ROCK1 | |
| SCHEMBL2801122 | 0.86 | ROCK2 (1.00) | ROCK2CCR2ROCK1 | |
| SCHEMBL2803836 | 0.86 | ROCK2 (1.00) | ROCK2CCR2ROCK1 | |
| SCHEMBL660852 | 0.86 | ROCK2 (1.00) | ROCK2CCR2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172324-A1 | METHOD FOR TREATING CARDIOVASCULAR DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130158014-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8410147-B2 | Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410147-B2 | Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130005756-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | NAVRATIL TOMAS (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299096-B2 | Method for treating pulmonary diseases using rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8207195-B2 | Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100204210-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20090325958-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325934-A1 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPATHIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325905-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325959-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325960-A1 | METHOD FOR TREATING INFLAMMATORY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325960-A1 | METHOD FOR TREATING INFLAMMATORY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | ROCK2 2/4885CCR2 162/4885ROCK1 1/4885 |
| US-20130158014-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885CCR2 2493/4885ROCK1 1/4885 |
| US-20130172324-A1 | METHOD FOR TREATING CARDIOVASCULAR DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | ROCK2 2/4885CCR2 1028/4885ROCK1 1/4885 |
| US-20090325958-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, RHOA, ROCK2 | ROCK2 3/4885CCR2 902/4885ROCK1 1/4885 |
| US-20090325905-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885CCR2 2493/4885ROCK1 1/4885 |
| US-20090325934-A1 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPATHIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | ROCK2 2/4885CCR2 642/4885ROCK1 1/4885 |
| US-20100204210-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, RHOA, SERPINB1 | ROCK2 4/4885CCR2 785/4885ROCK1 1/4885 |
| US-20090325959-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK2, ROCK1, CIT | ROCK2 1/4885CCR2 659/4885ROCK1 2/4885 |
| US-20130005756-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, RHOA, ROCK2 | ROCK2 3/4885CCR2 902/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.